<DOC>
	<DOC>NCT01975337</DOC>
	<brief_summary>The primary objective of the study was to compare the single dose pharmacokinetics of alisporivir in subjects with end stage renal disease (ESRD) on hemodialysis to those of matched healthy subjects. The secondary objective was to evaluate the safety and tolerability of a single dose of alisporivir when administered to subjects with ESRD.</brief_summary>
	<brief_title>Pharmacokinetics and Safety of Alisporivir in Subjects With End Stage Renal Disease on Hemodialysis Compared to Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Provides written informed consent before any assessment is performed Matched healthy participants are in good health as determined by past medical history, physical examination, vital signs, laboratory tests, and other assessments ESRD participants are on a protocoldefined stable hemodialysis regimen and have no evidence of hepatic decompensation, with vital signs and other tests within protocolspecified limits Weighs at least 50 kg Is able to communicate well with the investigator, to understand and comply with the requirements of the study. Has history or current use of overthecounter medications, dietary supplements, or drugs (including nicotine and alcohol) outside protocolspecified parameters Has signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise: 1. the safety or wellbeing of the participant or study staff; 2. the safety or wellbeing of the participant's offspring (such as through pregnancy or breastfeeding); 3. the analysis of results</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>